← Back to Search

PREVENT Program for Broken Bones

N/A

Recruiting

Led By Alexandra Papaioannou, MD, MSc

Research Sponsored by McMaster University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one year

Awards & highlights

Study Summary

This trial is studying a program called PREVENT that was designed to prevent hip fractures in older adults living in long-term care homes. Hip fractures are common in this population and can lead to hospitalization,

Who is the study for?

The PREVENT trial is for older adults in long-term care homes in Ontario and Alberta who are at risk of hip fractures due to osteoporosis and falls. Homes must have at least 70 residents to join. The study will use health records to identify eligible participants.Check my eligibility

What is being tested?

This trial tests the PREVENT program, which uses a fracture risk calculator and trains healthcare teams on fracture prevention strategies. It compares homes using this program with those that provide usual care to see if it reduces hip fractures.See study design

What are the potential side effects?

Since the intervention involves educational tools and processes rather than medications, there are no direct side effects like you'd expect from drugs. However, changes in care plans could indirectly affect resident well-being.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of hip-fractures

Secondary outcome measures

Change in health related quality of life

Change in level of pain

Change in medications and supplements

+6 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: PREVENT ProgramExperimental Treatment1 Intervention

Group II: Control GroupActive Control1 Intervention

Residents in homes allocated to the control group will receive usual care as provided within their home.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PREVENT Program

2022

N/A

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor

881 Previous Clinical Trials

2,594,826 Total Patients Enrolled

Alexandra Papaioannou, MD, MScPrincipal InvestigatorMcMaster University

7 Previous Clinical Trials

7,326 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment for this medical study currently accepting new participants?

"Indeed, clinicaltrials.gov indicates that this study is currently in the process of actively recruiting participants. The trial information was initially made available on September 1st, 2023, and the most recent update occurred on December 18th, 2023."

Answered by AI

What is the total number of individuals participating in this research trial?

"Indeed, as stated on clinicaltrials.gov, this ongoing clinical trial is actively seeking potential participants. The initial posting was made on September 1st, 2023 and the most recent update occurred on December 18th, 2023. For successful completion of the study, a total of 3060 patients are required to be enrolled from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care

Alexandra Papaioannou 2023. "The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04947722.